Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook

TheFly reported connected April 22 that The Goldman Sachs Group raised its standing connected GMAB from Neutral to Buy and acceptable a terms people of $30.50. The upgrade reflected expectations of a catalyst-heavy 2026, supported by renewed appraisal of cardinal pipeline assets including Epkinly, Rina-S, and petosemtamab. The steadfast highlighted combined highest income imaginable exceeding $5 cardinal crossed these programs, supporting a much favorable risk-reward profile. While acknowledging that the expiration of Darzalex royalty revenues is apt to measurement connected maturation opening successful 2029, it noted that this interaction is already mostly incorporated into existent valuation levels.

In the archetypal 4th of 2026, Genmab A/S (NASDAQ:GMAB) reported that planetary nett merchandise income of DARZALEX (daratumumab), including some intravenous and subcutaneous formulations, totaled $3.964 billion, arsenic disclosed by Johnson & Johnson. Sales were divided betwixt $2.208 cardinal successful the United States and $1.756 cardinal crossed planetary markets.

GMAB earns royalty income from worldwide DARZALEX income nether its licensing agreement, granting J&J exclusive rights to make and commercialize the therapy. The beardown quarterly show underscores continued request for the aggregate myeloma attraction crossed cardinal regions and contributes straight to Genmab’s royalty gross stream.

Genmab A/S (NASDAQ:GMAB) is simply a Denmark-based AI-driven biotechnology institution focused connected processing antibody-based crab therapies. It uses precocious AI crossed cause find and objective improvement to accelerate research, amended precision, and streamline biotech operations.

While we admit the imaginable of GMAB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 9 Most Undervalued Healthcare Stocks to Buy Now and 10 Most Undervalued Dow Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey connected Google News.